Movement Alert｜Revolution Medicines Falls 5.13% in Regular Trading, Profit-Taking After ASCO Pancreatic Cancer Data Rally

Market Focus06-02 22:40

On June 2, Revolution Medicines declined 5.13% in regular trading, trading at $153.18/share, with trading volume of $192 million. The pullback follows a sharp rally driven by the company's landmark Phase III RASolute 302 data presented at the ASCO annual meeting.

The sell-off reflects classic profit-taking after the stock had accumulated gains exceeding 15% in overnight and pre-market sessions on the preceding day. The ASCO presentation revealed that daraxonrasib doubled median overall survival to 13.2 months from 6.6 months for chemotherapy, and extended progression-free survival from 3.5 to 7.3 months in 500 previously treated metastatic pancreatic ductal adenocarcinoma patients. The data, simultaneously published in the New England Journal of Medicine, marks the first time a second-line pancreatic cancer therapy has pushed median OS beyond one year. While Oppenheimer raised its price target to $195, the magnitude of the prior surge created conditions for near-term profit-taking as the positive catalyst was fully absorbed by the market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104623161?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104623161","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Revolution Medicines Falls 5.13% in Regular Trading, Profit-Taking After ASCO Pancreatic Cancer Data Rally","media":"Market Focus","content":"<p><p>On June 2, Revolution Medicines declined 5.13% in regular trading, trading at $153.18/share, with trading volume of $192 million. The pullback follows a sharp rally driven by the company's landmark Phase III RASolute 302 data presented at the ASCO annual meeting.</p><p>The sell-off reflects classic profit-taking after the stock had accumulated gains exceeding 15% in overnight and pre-market sessions on the preceding day. The ASCO presentation revealed that daraxonrasib doubled median overall survival to 13.2 months from 6.6 months for chemotherapy, and extended progression-free survival from 3.5 to 7.3 months in 500 previously treated metastatic pancreatic ductal adenocarcinoma patients. The data, simultaneously published in the New England Journal of Medicine, marks the first time a second-line pancreatic cancer therapy has pushed median OS beyond one year. While Oppenheimer raised its price target to $195, the magnitude of the prior surge created conditions for near-term profit-taking as the positive catalyst was fully absorbed by the market.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Revolution Medicines Falls 5.13% in Regular Trading, Profit-Taking After ASCO Pancreatic Cancer Data Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Revolution Medicines Falls 5.13% in Regular Trading, Profit-Taking After ASCO Pancreatic Cancer Data Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-02 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 2, Revolution Medicines declined 5.13% in regular trading, trading at $153.18/share, with trading volume of $192 million. The pullback follows a sharp rally driven by the company's landmark Phase III RASolute 302 data presented at the ASCO annual meeting.</p><p>The sell-off reflects classic profit-taking after the stock had accumulated gains exceeding 15% in overnight and pre-market sessions on the preceding day. The ASCO presentation revealed that daraxonrasib doubled median overall survival to 13.2 months from 6.6 months for chemotherapy, and extended progression-free survival from 3.5 to 7.3 months in 500 previously treated metastatic pancreatic ductal adenocarcinoma patients. The data, simultaneously published in the New England Journal of Medicine, marks the first time a second-line pancreatic cancer therapy has pushed median OS beyond one year. While Oppenheimer raised its price target to $195, the magnitude of the prior surge created conditions for near-term profit-taking as the positive catalyst was fully absorbed by the market.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"","article_id":"1104623161","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104623161","pubTimestamp":1780411230,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 2, Revolution Medicines declined 5.13% in regular trading, trading at $153.18/share, with trading volume of $192 million. The pullback follows a sharp rally driven by the company's landmark...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc."},"translate_title":"动向提示|Revolution Medicines常规交易下跌5.13%ASCO胰腺癌数据反弹后获利了结","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1},"content_text":"On June 2, Revolution Medicines declined 5.13% in regular trading, trading at $153.18/share, with trading volume of $192 million. The pullback follows a sharp rally driven by the company's landmark Phase III RASolute 302 data presented at the ASCO annual meeting.The sell-off reflects classic profit-taking after the stock had accumulated gains exceeding 15% in overnight and pre-market sessions on the preceding day. The ASCO presentation revealed that daraxonrasib doubled median overall survival to 13.2 months from 6.6 months for chemotherapy, and extended progression-free survival from 3.5 to 7.3 months in 500 previously treated metastatic pancreatic ductal adenocarcinoma patients. The data, simultaneously published in the New England Journal of Medicine, marks the first time a second-line pancreatic cancer therapy has pushed median OS beyond one year. While Oppenheimer raised its price target to $195, the magnitude of the prior surge created conditions for near-term profit-taking as the positive catalyst was fully absorbed by the market.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104623161","isCrawlerRequest":true}